Evidence map›Paper›PMID 25069463›Full record

ArticleNature reviews. Endocrinology2014

Diabetes: safety and efficacy of albiglutide-results from two trials.

Giuseppe Derosa, Pamela Maffioli

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in Nature reviews. Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03199638 (Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03199638 nacompletednot on this mapstarted 2016, after this paper: background citation

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

TypeinterventionalSponsorNemours Children's ClinicRan2016 to 2017Enrolled14ConditionsDiabetes Mellitus, Type 1, Autoimmune Diseases, Diabetes Mellitus, Endocrine System DiseasesArmsGlutamine vs. Placebo, Exercise
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Giuseppe DerosaDepartment of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, P le C. Golgi 2, 27100 Pavia, Italy.
Pamela MaffioliDepartment of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, P le C. Golgi 2, 27100 Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control. The recent results from the HARMONY 3 and HARMONY 6 trials suggest that albiglutide is a safe and effective treatment option for patients with type 2 diabetes mellitus.

Indexed as

Diabetes Mellitus, Type 2FemaleGlucagon-Like Peptide 1HumansHypoglycemic AgentsMalePyrazinesSulfonylurea CompoundsTriazolesGlucagon-Like Peptide 1Hypoglycemic AgentsPyrazinesSulfonylurea CompoundsTriazoles

Identifiers

PMID25069463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.